Form 4: Gilead Sciences Director Acquires Stock Options

Gilead Sciences Director Kelly A. Kramer acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Summary

• Kelly A. Kramer, a Director at Gilead Sciences, Inc., acquired 1,146 restricted stock units (RSUs) and 4,884 non-qualified stock options on April 30, 2026.
• The RSUs represent the contingent right to receive one share of Gilead's common stock, and 100% vested immediately on the grant date.
• The stock options, with an exercise price of $130.84, also had 100% of the underlying shares vest immediately on the grant date.
• Following these transactions, Kramer beneficially owns 20,256 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction for compensation and does not provide new financial information or strategic outlook.

Positives

• Director Kelly A. Kramer's acquisition of restricted stock units and stock options indicates continued alignment with shareholder interests.
• Immediate vesting of both RSUs and stock options suggests confidence in the company's near-term prospects and management's commitment.
• The acquisition of 1,146 RSUs and 4,884 stock options demonstrates a significant personal investment in Gilead Sciences.

Future Outlook

This filing does not contain forward-looking statements or guidance. It solely reports on a transaction by a company insider.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of stock options and RSUs by directors, are common in the biopharmaceutical industry as a method of executive compensation and to align management's interests with those of shareholders. The immediate vesting of these awards can signal confidence in the company's current valuation and future performance.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as it aligns insider interests with shareholder value, though it is part of a compensation package.
• Employees: This transaction is related to executive compensation and does not directly impact general employee operations.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Keywords

Gilead Sciences, GILD, Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership